HCAT vs PHR

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 10, 2026

HCAT

52.4
AI Score
VS
HCAT Wins

PHR

38.8
AI Score

Investment Advisor Scores

HCAT

52score
Recommendation
HOLD

PHR

39score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric HCAT PHR Winner
Revenue 197.53M 260.39M PHR
Net Income -111.07M 4.88M PHR
Net Margin -56.2% 1.9% PHR
Operating Income -92.82M 14.36M PHR
ROE -76.3% 1.3% PHR
ROA -46.8% 0.8% PHR
Total Assets 237.42M 646.98M PHR
Current Ratio 1.70 1.76 PHR
Free Cash Flow 16.07M 37.45M PHR

Relative Price Performance (Last 90 Days)

HCAT 1M: -18.7% · 3M: -19.1% PHR 1M: +18.7% · 3M: +1.1%

Current Technical Phase

HCAT

Markdown
Sell / avoid

Price below a falling SMA50 (slope -2.6%), weak momentum, RSI 37

RSI (14): 37.1 · Price: $1.42

PHR

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 60

RSI (14): 60.0 · Price: $12.76

Fundamentals Snapshot

Metric HCAT PHR
Market Cap — —
Forward P/E -572.0 8.5
Trailing P/E — 77.2
Revenue (TTM) — —
Revenue Growth -0.3% 0.1%
Gross Margin 0.5% 0.7%
Operating Margin -0.2% 0.1%
EPS -2.80 0.17
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, HCAT is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.